[email protected]

+44 (0)20 3773 4895

logologologo
  • About Us
    • The College
    • Advisory Board
    • Our Faculty and Team
    • Intelligence Hub
  • Topic Areas
    • Obesity Care
    • Digital Health
    • Behaviour Change
  • Courses
    • CPD Short Courses
    • Academic Courses
      • Digital Health Courses
        • Postgraduate Certificate
        • Postgraduate Diploma
        • MSc in Digital Health
      • Obesity Courses
        • Postgraduate Certificate
        • Postgraduate Diploma
        • MSc in Obesity Care
  • Apply
    • Postgraduate Qualification in Obesity Care
    • Postgraduate Qualification in Digital Health
    • FAQs
  • Resources
    • News
    • Our Publications
    • Subscribe
    • Funding Options
  • Contact Us
    • Contact Us
  • Student Login

No products in the cart.

logologologo
  • About Us
    • The College
    • Advisory Board
    • Our Faculty and Team
    • Intelligence Hub
  • Topic Areas
    • Obesity Care
    • Digital Health
    • Behaviour Change
  • Courses
    • CPD Short Courses
    • Academic Courses
      • Digital Health Courses
        • Postgraduate Certificate
        • Postgraduate Diploma
        • MSc in Digital Health
      • Obesity Courses
        • Postgraduate Certificate
        • Postgraduate Diploma
        • MSc in Obesity Care
  • Apply
    • Postgraduate Qualification in Obesity Care
    • Postgraduate Qualification in Digital Health
    • FAQs
  • Resources
    • News
    • Our Publications
    • Subscribe
    • Funding Options
  • Contact Us
    • Contact Us
  • Student Login

No products in the cart.

  • About Us
    • The College
    • Advisory Board
    • Our Faculty and Team
    • Intelligence Hub
  • Topic Areas
    • Obesity Care
    • Digital Health
    • Behaviour Change
  • Courses
    • CPD Short Courses
    • Academic Courses
      • Digital Health Courses
        • Postgraduate Certificate
        • Postgraduate Diploma
        • MSc in Digital Health
      • Obesity Courses
        • Postgraduate Certificate
        • Postgraduate Diploma
        • MSc in Obesity Care
  • Apply
    • Postgraduate Qualification in Obesity Care
    • Postgraduate Qualification in Digital Health
    • FAQs
  • Resources
    • News
    • Our Publications
    • Subscribe
    • Funding Options
  • Contact Us
    • Contact Us
  • Student Login
April 19, 2018 by Nigel Hinchliffe GLP-1s & Medications 0 comments

How Physiological Changes Associated with Obesity Affect Drug Metabolism

Obesity is known to have a significant impact on many organ systems that are crucial in drug metabolism. As the prevalence of obesity continues to rise, clinicians are being challenged with the problem of dosing in the extreme overweight population. This review article discusses the different physiological changes associated with obesity and how they affect absorption, distribution, drug metabolism and clearance in morbidly obese patients.

The changes that occur in the organs of the body do not correlate linearly with BMI, but also includes factors such as time and individual body composition. For example, in the kidney of an obese patient, renal clearance is initially enhanced by a compensatory hyperfiltration and hyper-perfusion, though, eventually, this declines as a result of a constantly elevated intra-glomerular pressure which leads to chronic kidney disease. Likewise, cardiac output is increased in obese patients in order to provide oxygen and nutrients to the excess tissue. This should mean that that blood flow to the liver increases, however due to non-alcoholic fatty liver disease resulting in steatosis, together with sinusoidal narrowing, blood flow may actually decrease over time.

Obesity also has an effect on the gastric emptying and gut permeability, meaning that drugs are absorbed at different rates to normal. Drug penetration into tissue is also affected, meaning that a higher dose may be needed in order to reach effective concentrations. For example, with antibiotics to treat a local infection, obese patients may require a much higher dose, which can then introduce issues of drug toxicity.

What is clear from these few examples is that with a growing number of obese patients, there needs to be a quantitative system in place that can derive drug dosing recommendations for obese patients. Currently there is a lack of understanding of how obesity affects the pharmacokinetics and pharmacodynamics of drugs, which leads to improper and potentially dangerous dosing of obese patients.

To learn more about obesity, its prevention, and its treatment please look at CCH’s Postgraduate Academic Courses in Obesity Care, and CPD Short Courses in topics such as childhood obesity and behaviour change, designed to up-skill health professionals in this vitally important, and often overlooked, area of care.

PREV
NEXT

Related Posts

April 19, 2018
Efficacy, Safety, and Mechanisms Of Herbal Medicines Used In The Treatment Of Obesity: A Protocol For Systematic Review
Read More
City of London
February 23, 2022
Europe set to miss global heart health targets as obesity skyrockets
Read More
GLP-1 medications and a glass filled with sugar cubes on a table.
July 10, 2025
Tirzepatide outperforms other GLP-1 drugs in diabetes for blood sugar and weight loss
Read More
Human kneed joint bone model.
April 9, 2026
Weight Loss Drugs May Be Linked to Bone Health Risks, Five-Year Study Shows
Read More

CCH LINKS

FAQ
HOW TO APPLY
ACADEMIC ADVISORY BOARD
FACULTY AND STAFF
TERMS & CONDITIONS
CCH EDUCATION SERVICES

OUR PARTNERS

NOF
Haringey Obesity Alliance
Skills Active
CPD UK
ASO
REPS
Southwark
DIT
Healthcare Uk
OAC

ABOUT CCH

CONTACT US
[email protected]
+44 (0)20 3773 4895
Technopark, 90 London Road, LONDON, SE1 6LN
 

© The College of Contemporary Health